Yesterday 75 members of Congress, led by Rep. Chris Smith of New Jersey and Sen. James Lankford of Oklahoma, sent a letter to the Commissioner of the Food and Drug Administration demanding answers to questions about the FDA’s surprise approval of relaxed protocols for the distribution of the abortion-inducing drug regimen known as Mifeprex. The changes, announced on March 30, significantly increase the duration of pregnancy at which the drug regimen may be administered, raising it from 49 days (7 weeks) from the last menstrual period (LMP) to 70 days (10 weeks) post-LMP.
On April 20, the U.S. House of Representatives’ Select Investigative Panel on Infant Lives will hold a hearing on “The Pricing of Fetal Tissue” in response to information brought forth by the Center for Medical Progress’ undercover video exposé.
Charlotte Lozier Institute’s new associate scholar Catherine Glenn Foster, J.D. has been invited to testify as an attorney on the federal statutes governing fetal tissue research. Below is a preview of her testimony.
On April 14, the House Judiciary Committee held a hearing on HR 4924, the Prenatal Nondiscrimination Act (PRENDA) of 2016, sponsored by Rep. Trent Franks. The bill would prohibit discrimination against the unborn based on the preference of sex or race alone. Charlotte Lozier Institute associate scholar Anna Higgins, J.D. testified in support of the bill, and summarized her newly published paper on sex-selection abortion.
Beginning in the 1990’s, and throughout the first years of the 21st century, perhaps no other political or social cause célèbre attracted as many celebrities as human embryonic stem cell research (hESCR).
Christopher Reeve, Kevin Kline, Michael J. Fox and Mary Tyler Moore, among others, all made their way to Capitol Hill to testify in support of increased federal funding of hESCR (during her congressional testimony on behalf of the Juvenile Diabetes Foundation, Ms. Moore famously said human embryos have “no more resemblance to a human being than a goldfish”)…
Despite advances in civil rights and the recognition by most developed nations that discrimination on the basis of sex alone is inherently unjust, a very real and pervasive form of sex discrimination is still permitted and practiced in the world today. Prenatal sex discrimination crosses cultural, ethnic, and national lines. It is practiced with impunity in many countries, including the U.S., via sex-selective abortion – choosing to abort a preborn child based solely on the child’s sex.
Last week, the Food and Drug Administration (FDA) changed the regulations for RU-486, the “abortion pill,” allowing its use up to 70 days into pregnancy, three weeks past the previous guidelines. On the same day, Abby Johnson’s The Walls Are Talking: Former Abortion Clinic Workers Tell Their Stories, was officially released. One chapter in particular stood out as especially timely in regards to the news: “Medication Abortion.”
The Minnesota Department of Health publishes an extensive and organized annual abortion report that presents important public health information, including demographic statistics, while protecting the anonymity of women. Additionally, Minnesota reports the volume of abortions performed at each clinic in the state.
Minnesota’s abortion trends provide a glimpse of what is happening to the abortion market on a national scale. Similar to national trends, the total number abortions in Minnesota has decreased, one abortion clinic has closed, several have merged, and Planned Parenthood increasingly dominates the market.